Pharmacological management of children and adolescents with attention-deficit/hyperactivity disorder (ADHD) often results in improvements in symptoms of inattention (distractibility, forgetfulness, inability to concentrate), in symptoms of hyperactivity-impulsivity (restlessness, fidgetiness, impulsive responses), and in overall quality of life ([@b5-ndt-3-293]; [@b24-ndt-3-293]). Sympathomimetic stimulants are the most common treatment for ADHD ([@b5-ndt-3-293]; [@b2-ndt-3-293]), but a sizable minority of children and adolescents with ADHD do not respond adequately to these medications or have intolerable side-effects ([@b5-ndt-3-293]; [@b24-ndt-3-293]). Thus, additional treatments for ADHD are sought. Modafinil has been evaluated as a potentially effective medication in reducing problematic symptoms of ADHD.

Molecular and biologic characteristics of modafinil
===================================================

Modafinil (Provigil^®^, Cephalon, Inc., Frazer, PA, USA) is a wakefulness-promoting medication that is structurally different from the classical stimulants (methylphenidate, amphetamines, and pemoline; see [Figure 1](#f1-ndt-3-293){ref-type="fig"}). Besides being structurally unique, the neurophysiological properties of modafinil are also unique in comparison with sympathomimetic stimulants ([@b27-ndt-3-293], [@b26-ndt-3-293]; [@b37-ndt-3-293]; [@b36-ndt-3-293]; [@b16-ndt-3-293]). Besides a low affinity for the dopamine reuptake carrier site with only a slight increase in extracellular dopamine ([@b28-ndt-3-293]), modafinil does not bind to nor does it have significant agonist or antagonist activity at any of the known CNS neuronal catecholamine, cholinergic or amino acid/neuropeptide receptors or transporters ([@b9-ndt-3-293]). In contrast to the sympathomimetic stimulants, physiological effects of modafinil are not a direct result of dopaminergic or noradrenergic activity ([@b1-ndt-3-293]; [@b14-ndt-3-293]; [@b16-ndt-3-293]).

Whereas methylphenidate and amphetamine stimulants have a wide distribution of direct neuronal activity throughout the cortex, basal ganglia, and nucleus accumbens, preclinical studies of modafinil demonstrate more limited binding, primarily in the hypothalamus ([@b26-ndt-3-293]). Increased neuronal activity (as evidenced by increased c-fos activity) was found primarily in orexin neurons of the tuberomammilary nucleus, even with administration of low doses of modafinil ([@b34-ndt-3-293]). This area of the brain is implicated in regulating physiologic wakefulness ([@b7-ndt-3-293]; [@b34-ndt-3-293]). Evidence also exists for inhibition of the sleep-promoting neurons of the ventrolateral preoptic nucleus after modafinil adminstration ([@b17-ndt-3-293]).

Notable in these preclinical studies is the lack of significant activity in the nucleus accumbens ([@b26-ndt-3-293]; [@b16-ndt-3-293]; [@b34-ndt-3-293]), the brain's reward/reinforcement center (which mediates most of the addictive properties of drugs such as cocaine, opioids, and stimulants). Several studies have confirmed the low abuse potential of modafinil ([@b13-ndt-3-293]; [@b29-ndt-3-293]), with less cocaine-like discriminative-stimulus effects and self-reported stimulant effects than methylphenidate or amphetamines ([@b19-ndt-3-293]; [@b22-ndt-3-293]; [@b23-ndt-3-293]; [@b32-ndt-3-293], [@b33-ndt-3-293]).

Although approved by the US Food and Drug Administration for improving wakefulness in adults with excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea, and shift work sleep disorder 16 years of age and older ([@b8-ndt-3-293]), its mechanism of action in humans is not fully understood. After administration of modafinil, functional MRI (fMRI) has shown activation of the anterior cingulate cortex during a task of working memory ([@b38-ndt-3-293]), and an activation of other cortical areas (particularly in individuals with low initial activation levels; [@b15-ndt-3-293]). This is very significant, considering that the anterior cingulate cortex was notably deficient in fMRI activity in individuals with ADHD during a working memory task ([@b6-ndt-3-293]). A likely hypothesis regarding modafinil's physiologic effects is that modafinil indirectly activates the cerebral cortex (including areas implicated in ADHD pathology) via ascending arousal pathways arising from the hypothalamus (eg, the tuberomammillary nucleus; see [Figure 2](#f2-ndt-3-293){ref-type="fig"}).

Modafinil is well absorbed from the gastrointestinal tract, but bioavailability cannot he determined since low water solubility makes i.v. administration unfeasible ([@b8-ndt-3-293], [@b9-ndt-3-293]). Peak levels are seen at 2--4 hours after oral administration, but about 1 hour later if administered with food ([@b8-ndt-3-293],[@b9-ndt-3-293]). Metabolized by several cytochrome P450 (CYP450) enzymes, modafinil is a mild inducer of CYP1A2, CYP2B6, CYP3A4, and is a mild inhibitor of CYP2C19 ([@b8-ndt-3-293]). Therefore, interactions with medicines may be seen with diazepam, propranolol, phenytoin, S-mephenytoin, and tricyclic or some SSRI antidepressants (in poor metabolizers of CYP2D6), whereas decreased efficacy of added medicines may be seen with cyclosporine and birth control hormones ([@b8-ndt-3-293]). Strong CYP3A4 inducers (such as carbamazepine, phenobarbital, and rifampin) or inhibitors (such as ketoconazole or itraconazole) may slightly alter modafinil blood levels ([@b8-ndt-3-293]).

Half-life in adults is approximately 15 hours, but is shorter for children and adolescents. For children 6--7 years of age, the half-life is about 7 hours ([@b9-ndt-3-293]). The half-life gradually lengthens until 9--11 years, when a pronounced shift is seen approaching adult levels ([@b9-ndt-3-293]).

Efficacy in children and adolescents with ADHD
==============================================

After two investigator-initiated independent studies suggested possible efficacy of modafinil in children with ADHD ([@b30-ndt-3-293]; [@b31-ndt-3-293]), a phase 2 study of 248 children and adolescents aged 6--13 years was completed to determine if divided doses were effective, tolerated, and necessary to treat children with ADHD. The subjects who received 300 mg once per day showed consistently greater improvement in home and school ADHD Rating Scale IV (ADHD-RS-IV; [@b12-ndt-3-293]) total scores as well as in Conners Parent Rating Scales (CPRS; Connors 1997) ADHD DSM-IV total scores, whereas subjects who received 300 mg per day in divided doses showed less consistent improvements in ADHD symptoms ([@b4-ndt-3-293]). The pharmacokinetic data from this and other phase 2 studies allowed for computer modeling of the exposure -- response relationship. Using a target range for the area under the plasma drug concentration versus time curve (AUC~0--24~) of 150 μg × hours/mL, doses of 340 mg/day were found to be the most appropriate target dose if the child's weight was \<30 kg and 425 mg/day if the child's weight was ≥30 kg ([@b9-ndt-3-293]).

Three phase 3 studies involving a total of 638 children and adolescents with ADHD aged 6 to 17 years confirmed the clinical efficacy of 85 mg modafinil film-coated compressed tablets when administered as once-daily doses of up to 340--425 mg over 7--9 weeks ([@b3-ndt-3-293]; [@b40-ndt-3-293]; [@b20-ndt-3-293]). For each of the studies, the diagnosis of ADHD was confirmed with the Diagnostic Interview Schedule for Children, Fourth Edition (DISC IV), and severity of illness was confirmed with scores ≥1.5 standard deviations above the age- and gender-based mean on the ADHD-RS-IV: School Version. Mental impairment, uncontrolled psychological comorbidity, and significant medical problems excluded subjects from these studies. As is observed in most ADHD studies involving children and adolescents, most of the subjects of these studies ([@b3-ndt-3-293]; [@b40-ndt-3-293]; [@b20-ndt-3-293]) had ADHD, Combined Type (59%--71%), were male (2.4--2.7:1), and were moderately to markedly ill (82%--91%).

Two flexible-dose studies ([@b3-ndt-3-293]; [@b20-ndt-3-293]) and one fixed-dose study ([@b40-ndt-3-293]) documented efficacy of a film-coated compressed tablet formulation of modafinil using an intent-to-treat analysis with 2:1 ratio of treatment: control and with the endpoint defined as the last obtained value carried forward. In the flexible-dose studies, the mean and modal stable doses were 361--369 mg/day and 425 mg/day (range 170--425 mg once daily every morning), whereas the final administered dose in the fixed-dose study was 340 mg for children \<30 kg and 425 mg for subjects ≥30 kg. For all three studies and for pooled data ([@b9-ndt-3-293]), ADHD-RS-IV scores demonstrated improvements consistently in favor of modafinil for the primary outcome measure (the School Version of the ADHD-RS-IV, see [Figures 3a](#f3a-ndt-3-293){ref-type="fig"}, [b](#f3b-ndt-3-293){ref-type="fig"}, [c](#f3c-ndt-3-293){ref-type="fig"}), the Home Version of the ADHD-RS-IV, as well as for the inattentive and hyperactive-impulsive subscale scores of each version. There were no effects of race, sex, weight, ADHD subtype, or comorbidity in the improvements seen with modafinil treatment ([@b9-ndt-3-293]). More improvement was seen in patients less than 12 years of age compared with older patients. Modafinil was efficacious in treating both stimulant-naïve patients and those who had received prior stimulant therapy. ADHD-RS-IV: School Version total scores showed a reduction of ≥30% in 64%--69% of modafinil-treated subjects (as compared with 35%--39% of controls, p \< 0.0001) and a reduction of ≥50% for 44%--48% of modafinil-treated subjects as compared with 19%--20% of controls, p \< 0.001) for each of the studies ([@b3-ndt-3-293]; [@b40-ndt-3-293]; [@b9-ndt-3-293]; [@b20-ndt-3-293]). Using the ADHD-RS-IV: School Version total score data and Cohen's calculations, the overall pooled effect size was 0.69; this corresponds to a medium-to-large effect (Cohen 1988). The greatest effect was seen in drug-naïve subjects, in whom the calculated effect size was 1.08 (treatment n = 221 and control n = 102).

For all three of these double-blind, placebo-controlled studies ([@b9-ndt-3-293]), the ADHD Rating Scale-IV scores continued to improve while subjects were followed week-to-week (see [Figure 3](#f3a-ndt-3-293){ref-type="fig"}). Nonetheless, improvements were often seen at the first follow-up visit (week 1 of treatment; [@b40-ndt-3-293]; [@b20-ndt-3-293]).

[Figure 4](#f4a-ndt-3-293){ref-type="fig"} outlines the Clinical Global Impression of Change ratings from these studies ([@b9-ndt-3-293]), defining a clinical response as "very much improved" or "much improved." Patients treated with modafinil showed greater improvement in overall clinical condition than those receiving placebo at all study visits and for the last observation carried forward (46% vs 18%). Based on the pooled data ([@b9-ndt-3-293]), the number needed to treat was 3.5 (95% confidence interval = 2.8--4.7).

Using the Social Skills Rating Scale (SSRS; [@b21-ndt-3-293]), statistically significant improvements favoring modafinil treatment were seen at endpoint for the externalizing subscale score, the internalizing subscale score, and the hyperactivity subscale score as well as for the problem behaviors total score ([@b3-ndt-3-293]; [@b40-ndt-3-293]; [@b9-ndt-3-293]; [@b20-ndt-3-293]). Along with reductions in problem behaviors, the SSRS analysis suggested that modafinil resulted in improvements in the subscale scores for cooperation, assertion, responsibility, and self-control ([@b3-ndt-3-293]; [@b40-ndt-3-293]; [@b9-ndt-3-293]; [@b20-ndt-3-293]).

Safety and tolerability
=======================

The 7-week fixed-dose study was followed by an abrupt double-blind, placebo-controlled 2-week withdrawal from treatment ([@b40-ndt-3-293]). No withdrawal symptoms, rebound exacerbation of ADHD symptoms, or rebound hypersomnolence was reported from the subjects who were abruptly withdrawn from modafinil.

During the three cited double-blind, placebo-controlled studies ([@b3-ndt-3-293]; [@b40-ndt-3-293]; [@b20-ndt-3-293]), 420 subjects received modafinil treatment; 55% of subjects had at least one treatment-related adverse event, as compared with 29% of control patients ([@b9-ndt-3-293]). Since the flexible-dose studies ([@b3-ndt-3-293]; [@b20-ndt-3-293]) proceeded with a slower upward titration (over the course of 3 weeks) than the fixed-dose study (over the course of 7--9 days; [@b40-ndt-3-293]), and since the flexible-dose studies halted upward titration when adequate efficacy was determined, the frequency of adverse events was lower in the flexible dose studies than in the fixed dose study. In each of the flexible dose studies ([@b3-ndt-3-293]; [@b20-ndt-3-293]), modafinil-treated patients did not discontinue the study because of an adverse event at a rate higher than placebo, whereas more modafinil-treated subjects discontinued the study for an adverse event than control subjects (10% vs 0%) in the fixed dose study ([@b40-ndt-3-293]).

[Table 1](#t1-ndt-3-293){ref-type="table"} describes the adverse events that occurred in at least 5% of the modafinil-treated patients and that occurred more frequently than in the control group ([@b9-ndt-3-293]). When analyzing the pooled data ([@b9-ndt-3-293]), Seventyfive percent of the adverse events developed within the first 2 weeks of treatment (during upward dose titration). Insomnia was the most frequent adverse event ([@b3-ndt-3-293]; [@b40-ndt-3-293]; [@b9-ndt-3-293]; [@b20-ndt-3-293]), was described as severe in 9 cases and resulted in discontinuation of modafinil in 5 cases. Insomnia, headache, and gastrointestinal concerns (loss of appetite or abdominal pain) were the most common adverse events that resulted in discontinuation, but fever and nervousness were also rare causes for discontinuation ([@b3-ndt-3-293]; [@b40-ndt-3-293]; [@b9-ndt-3-293]; [@b20-ndt-3-293]).

Anorexia/decreased appetite was reported in 16% of subjects ([@b3-ndt-3-293]; [@b40-ndt-3-293]; [@b9-ndt-3-293]; [@b20-ndt-3-293]) and was associated with a 0.7 kg decrease of body weight during the 7--9 weeks of treatment of the three phase 3 studies (compared with the control group that gained 1 kg during the same time period). However, during a 12 month open-label extension study ([@b9-ndt-3-293]) that followed the phase 3 studies, the weight z scores (compared with the norms established by the National Center for Health Statistics; Kucsmanski et al 2000) indicated that the subjects were heavier than average at baseline, and the z scores stabilized after 3 months of treatment. On the other hand, height z scores did not appear to decline over the 12-month extension period ([@b9-ndt-3-293]).

No significant changes in resting heart rate, resting blood pressure, or electrocardiographic findings were found with administration of modafinil in doses from 85 mg to 425 mg ([@b3-ndt-3-293]; [@b40-ndt-3-293]; [@b9-ndt-3-293]; [@b20-ndt-3-293]).

Among all children and adolescents who were administered modafinil as a part of clinical studies for ADHD (n = 933; [@b9-ndt-3-293]), a total of 18 serious adverse events were described. Of these, only two were reported as "probably" or "possibly" related to modafinil: a maculopapular/morbiliform rash and a case of possible erythema multiforme/Stevens-Johnson Syndrome ([@b3-ndt-3-293]). All of these skin lesions resolved without sequelae ([@b9-ndt-3-293]). Six additional subjects (n = 933) discontinued modafinil treatment for concerns of rash, with resolution [@b9-ndt-3-293]). Post-marketing experience was reviewed in light of these skin concerns. Five reports of severe cutaneous adverse reactions have been made since 1999, during which time approximately 673,000 adults have taken modafinil worldwide ([@b9-ndt-3-293]). Further studies evaluating the relationship between the skin rashes and modafinil/modafinil sulfone have been requested by the United States Food and Drug Administration.

Psychiatric adverse events, such as aggression, suicidal ideation, and psychosis/mania were recently reported to be consequences of the various medications used to treat ADHD ([@b18-ndt-3-293]). In double-blind and open-label studies for children and adolescents with ADHD (n = 933, [@b9-ndt-3-293]), aggression was reported for 1.4 to 1.8% of subjects taking modafinil. A total of 5 subjects reported symptoms of psychosis/mania (one of whom required hospitalization) and 5 reported transient suicidal ideation (most of whom had resolution despite continuing modafinil treatment). As observed with other ADHD treatments (Celpirin 2006), many of these subjects had no prior remarkable history of similar events.

Conclusion
==========

Modafinil, when titrated to effect with a target dose of 340 mg (body weight \<30 kg) or 425 mg (body weight ≥30 kg) over the course of 2--3 weeks, is effective in managing the symptoms of and the problem behaviors associated with attention-deficit/hyperactivity disorder in children and adolescents. It is generally well tolerated, with adverse events (such as insomnia, headache, loss of appetite, weight loss, and gastrointestinal discomfort) generally being mild to moderate (and rarely leading to medication discontinuation). Close observation (especially during the first 4 weeks of treatment) may be necessary to watch for the development of a skin rash.
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![Chemical structures of modafinil, methylphenidate, amphetamine, and pemoline.](ndt-3-293f1){#f1-ndt-3-293}

![Indirect activation of the cerebral cortex by modafinil action on the tuberomammillary nucleus. Adapted from [@b39-ndt-3-293].\
**Abbreviations:** SN, suprachiasmatic nucleus; TMN, tuberomammilary nucleus; VTA, ventral tegmental area.](ndt-3-293f2){#f2-ndt-3-293}

![ADHD Rating Scale total scores as a function of time in a flexible-dose study of efficacy of modafinil for children and adolescents with attention-deficit/hyperactivity disorder (n = 194). \*p values \<0.05; endpoint represents the last obtained value carried forward Reproduced from Cephalon, Inc. 2006. Modafinil (CEP-1538) tablets Supplemental NDA 20-717/S-019 ADHD indication. Briefing document for Psychopharmacologic Drugs Advisory Committee Meeting March 26, 2006. Frazer, PA: Cephalon, Inc.](ndt-3-293f3a){#f3a-ndt-3-293}

![ADHD Rating Scale total scores as a function of time for a flexible-dose study of modafinil efficacy for children and adolescents with attention-deficit/hyperactivity disorder (n = 244). \*p values \<0.05; endpoint represents the last obtained value carried forward. Reproduced from: Cephalon, Inc. 2006. Modafinil (CEP-1538) tablets Supplemental NDA 20-717/S-019 ADHD indication. Briefing document for Psychopharmacologic Drugs Advisory Committee Meeting March 26, 2006. Frazer, PA: Cephalon, Inc.](ndt-3-293f3b){#f3b-ndt-3-293}

![ADHD Rating Scale total scores as a function of time for a fixed-dose study of efficacy of modafinil for children and adolescents with attention-deficit/hyperactivity disorder (n = 183). \*p values \<0.05; endpoint represents the last obtained value carried forward Reproduced from Cephalon, Inc. 2006. Modafinil (CEP-1538) tablets Supplemental NDA 20-717/S-019 ADHD indication. Briefing document for Psychopharmacologic Drugs Advisory Committee Meeting March 26, 2006. Frazer, PA: Cephalon, Inc.](ndt-3-293f3c){#f3c-ndt-3-293}

![Percentage responders as a function of time for a flexible-dose study of efficacy of modafinil for children and adolescents with attention-deficit/hyperactivity disorder (n = 194). Response is defined as having a Clinical Global Impressions of Change score of 1 ("very much improved") or 2 ("much improved").\
\*p values \<0.05; EP = endpoint, which represents the last obtained value carried forward. Reproduced from Cephalon, Inc. 2006. Modafinil (CEP-1538) tablets Supplemental NDA 20-717/S-019 ADHD indication. Briefing document for Psychopharmacologic Drugs Advisory Committee Meeting March 26, 2006. Frazer, PA: Cephalon, Inc.](ndt-3-293f4a){#f4a-ndt-3-293}

![Percentage responders as a function of time for a flexible-dose study of efficacy of modafinil for children and adolescents with attention-deficit/hyperactivity disorder (n = 244). Response is defined as having a Clinical Global Impressions of Change score of 1 ("very much improved") or 2 ("much improved"). \*p values \<0.05; EP = endpoint, which represents the last obtained value carried forward. Reproduced from Cephalon, Inc. 2006. Modafinil (CEP-1538) tablets Supplemental NDA 20-717/S-019 ADHD indication. Briefing document for Psychopharmacologic Drugs Advisory Committee Meeting March 26, 2006. Frazer, PA: Cephalon, Inc.](ndt-3-293f4b){#f4b-ndt-3-293}

![Percentage responders as a function of time for a fixed-dose study of efficacy of modafinil for children and adolescents with attention-deficit/hyperactivity disorder (n = 183). Response is defined as having a Clinical Global Impressions of Change score of 1 ("very much improved") or 2 ("much improved"). \*p values \<0.05; EP = endpoint, which represents the last obtained value carried forward. Reproduced from Cephalon, Inc. 2006. Modafinil (CEP-1538) tablets Supplemental NDA 20-717/S-019 ADHD indication. Briefing document for Psychopharmacologic Drugs Advisory Committee Meeting March 26, 2006. Frazer, PA: Cephalon, Inc.](ndt-3-293f4c){#f4c-ndt-3-293}

###### 

Adverse events occurring in at least 5% of modafinil-treated subjects which occurred more frequently than in the control group during the three phase 3 studies (pooled data)

                               Number (%)   of subjects
  ---------------------------- ------------ -------------
  Insomnia                     115 (27)     8 (4)
  Headache                     82 (20)      27 (13)
  Anorexia/appetite decrease   67 (16)      6 (3)
  Abdominal pain               40 (10)      17 (8)
  Fever                        21 (5)       7 (3)
  Nervousness                  19 (5)       9 (4)

Reproduced from Cephalon, Inc. Modafinil (CEP-1538) tablets Supplemental NDA 20-717/S-019 ADHD Indication. Briefing document for Psychopharmacologic Drugs Advisory Committee Meeting March 23, 2006. Frazer, PA: Cephalon, Inc.
